2026 International Fall Summit
October 28, 2026 | 12:00 PM EST
- Home
- Clinical Resources Search
- PQI: Reflex Biomarker Testing in Metastatic Colorectal Cancer: Implementing BRAF and MSI Assessment
Reflex Biomarker Testing in Metastatic Colorectal Cancer: Implementing BRAF and MSI Assessment
About this PQI
This resource outlines a workflow for reflex biomarker testing in first-line metastatic colorectal cancer (mCRC), focusing on BRAF and microsatellite instability (MSI)/mismatch repair (MMR) status to support timely treatment decisions.
How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.
Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQIFind Similar Resources
All Resources
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Cetuximab
Last Updated: 04/08/2026
Irinotecan
Last Updated: 02/03/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
Patient Education Sheet
PQI
Patient Education Sheet
Patient Education Sheet
Encorafenib
Last Updated: 06/26/2026
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
Encorafenib and Binimetinib
Last Updated: 08/09/2024
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Cetuximab
Last Updated: 04/08/2026
Cetuximab plus Radiation
Last Updated: 03/09/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
Patient Education Sheet
PQI
Patient Education Sheet
Patient Education Sheet
Encorafenib
Last Updated: 06/26/2026
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
Encorafenib and Binimetinib
Last Updated: 08/09/2024
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Cetuximab
Last Updated: 04/08/2026
Cetuximab plus Radiation
Last Updated: 03/09/2026
Encorafenib, Cetuximab and FOLFOX
Last Updated: 01/12/2026
PQI
Patient Education Sheet
PQI
PQI: Amivantamab and Hyaluronidase plus Lazertinib Patient Management
Last Updated: 04/08/2026
Amivantamab and Lazertinib
Last Updated: 03/11/2026
PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol
Last Updated: 08/07/2025
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
Romidepsin
Last Updated: 07/06/2026
Cyclophosphamide Given by Infusion
Last Updated: 07/06/2026
Decitabine/Cedazuridine and Venetoclax
Last Updated: 07/06/2026
Fludarabine and Cyclophosphamide
Last Updated: 06/29/2026